Study analysis · The Journal of clinical endocrinology and metabolism · 2012
A liver hormone called FGF21 plunges 60 minutes after a glucose drink—then rebounds by 180—and in healthy people, its swings move opposite to insulin.
In a small study, people with worse blood sugar had higher fasting FGF21, and after a sugary drink FGF21 dipped then rose in everyone, but only healthy people showed an inverse link between FGF21 changes and insulin changes.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched how a hormone called FGF21 changes after people drink a sugary drink. It found that the hormone and blood sugar/insulin levels move together, but it can't prove that the hormone causes those changes. We can only say they are linked, not that one causes the other.
What’s the bottom line?
Researchers gave 59 people a sugary drink (75 g glucose) and measured a hormone called FGF21. They compared healthy people, people with prediabetes, and people with type 2 diabetes.
How strong is this study?
The study only included 59 people and we only read a short summary, not the full details. That means we don't know if there were problems with how the study was done, so we should be careful about trusting the results too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=59)+5.1/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 532 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. Observational cross-sectional design with no randomization or control group; cannot establish cause-effect relationships. Only associations can be inferred.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were declared in the provided study text.
The provided text does not include a conflict of interest, funding, or author affiliation section. This limits a full assessment, but no industry ties or conflicts are evident from the available information.
Key takeaways
- 01
Fasting FGF21 was higher across healthy, prediabetes, and type 2 diabetes groups (P<0.05 for trend).
- 02
After the glucose drink, FGF21 dropped to its lowest point at 60 minutes and rose to its highest at 180 minutes in all groups.
- 03
FGF21 levels went in the opposite direction to glucose levels.
- 04
In healthy people, FGF21 changes were inversely linked to insulin changes (P=0.012) and C-peptide changes (P=0.043); this link was not seen in prediabetes or type 2 diabetes.
- 05
No relative or absolute effect sizes were reported.
- 06
The study reports only P values and no effect sizes, so the size of the effect for a person cannot be calculated from the abstract.
- 07
Absolute risk increases or absolute differences were not reported in this study.
Practical takeaways
No practical action is supported by this abstract. It is an early mechanistic study; do not change diet, medication, or supplement use based on these findings.
Abstract-only; small sample (n=59), acute single-visit design, no effect sizes or absolute risks reported; full methodology not available.
low confidenceWhy this study matters
FGF21 rises with worsening glucose tolerance
Fasting serum FGF21 increased progressively from healthy (n=20) to impaired glucose tolerance (n=18) to type 2 diabetes (n=21), with P<0.05 for global trend. No effect sizes or absolute levels were reported in the abstract.
It suggests the body may ramp up this hormone as glucose control deteriorates, but we cannot tell how large the difference is.
The 60-minute dip and 180-minute rebound
During a 75-g oral glucose tolerance test, FGF21 followed a biphasic pattern in all three groups: it fell to a nadir at 60 minutes, then rose to a peak at 180 minutes. This was a similar pattern regardless of glucose tolerance status.
Most people expect hormones to rise after eating; this one dips first. It is a counterintuitive acute response.
Opposite to glucose—and in healthy people, opposite to insulin
FGF21 levels at different OGTT time points negatively correlated with glucose levels across all subjects. In healthy subjects, FGF21 fold changes were inversely associated with insulin fold changes (P=0.012) and C-peptide fold changes (P=0.043). This inverse association was not seen in IGT or T2DM.
The link between FGF21 and insulin appears disrupted in prediabetes and diabetes, hinting at early metabolic changes.
Small sample, big caveats
The study included only 59 people total (20 healthy, 18 IGT, 21 T2DM) and was a single-visit acute test. The abstract reports P values but no effect sizes, confidence intervals, or absolute risks.
It is a reminder to read beyond headlines: a statistically significant trend in a small study may not translate into a meaningful personal effect.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers gave 59 people a sugary drink (75 g glucose) and measured a hormone called FGF21. They compared healthy people, people with prediabetes, and people with type 2 diabetes.
Research results
Fasting FGF21 was higher across healthy, prediabetes, and type 2 diabetes groups (P<0.05 for trend). After the glucose drink, FGF21 dropped to its lowest point at 60 minutes and rose to its highest at 180 minutes in all groups. FGF21 levels went in the opposite direction to glucose levels. In healthy people, FGF21 changes were inversely linked to insulin changes (P=0.012) and C-peptide changes (P=0.043); this link was not seen in prediabetes or type 2 diabetes. No relative or absolute effect sizes were reported.
What this means - more context
The study reports only P values and no effect sizes, so the size of the effect for a person cannot be calculated from the abstract. Absolute risk increases or absolute differences were not reported in this study.
To investigate acute changes in serum fibroblast growth factor 21 (FGF21) in response to a 75-g oral glucose challenge in humans.
In a 75-g oral glucose tolerance test among 20 healthy, 18 impaired glucose tolerance (IGT), and 21 type 2 diabetes mellitus (T2DM) subjects, fasting serum FGF21 rose progressively across groups (P<0.05 for global trend). After glucose intake, FGF21 showed a similar biphasic pattern in all groups: nadir at 60 min, peak at 180 min. FGF21 levels negatively correlated with glucose at multiple time points. In healthy subjects, fold changes in FGF21 were inversely associated with fold changes in insulin (P=0.012) and C-peptide (P=0.043), but not in IGT/T2DM. No relative or absolute effect sizes or absolute risks were reported.
Methods Used
A 75-g oral glucose tolerance test was performed in 20 healthy subjects, 18 with impaired glucose tolerance, and 21 with type 2 diabetes mellitus. Blood samples were collected for FGF21 and other biochemical parameters; associations of FGF21 with insulin and metabolic parameters were analyzed. Full methodology details not available in abstract.
Main Finding
Fasting serum FGF21 increased progressively from healthy to IGT to T2DM (P<0.05 for global trend). During OGTT, FGF21 fell to a nadir at 60 min and rose to a peak at 180 min in all groups. FGF21 levels negatively correlated with glucose levels. In healthy subjects, FGF21 fold change was inversely associated with insulin fold change (P=0.012) and C-peptide fold change (P=0.043), but not in IGT or T2DM. No relative or absolute effect sizes, confidence intervals, or absolute risk estimates were reported in the abstract.
Confidence Level
Limited - based on abstract only, full methodology not available; small sample, acute single-visit design, no effect sizes or CIs reported.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Small sample size (20 healthy, 18 IGT, 21 T2DM) and acute single-visit design
- •No effect sizes, confidence intervals, or absolute risk estimates reported in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
No practical action is supported by this abstract. It is an early mechanistic study; do not change diet, medication, or supplement use based on these findings.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 532 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study watched how a hormone called FGF21 changes after people drink a sugary drink. It found that the hormone and blood sugar/insulin levels move together, but it can't prove that the hormone causes those changes. We can only say they are linked, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Controlled oral glucose challenge with repeated measures
- Comparison across three glucose tolerance groups
- Measures of insulin and C-peptide alongside FGF21
Weaknesses
- Full methodology not available - based on abstract only
- Observational cross-sectional design
- No randomization
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers gave 59 people a sugary drink (75 g glucose) and measured a hormone called FGF21. They compared healthy people, people with prediabetes, and people with type 2 diabetes.
Research results
Fasting FGF21 was higher across healthy, prediabetes, and type 2 diabetes groups (P<0.05 for trend). After the glucose drink, FGF21 dropped to its lowest point at 60 minutes and rose to its highest at 180 minutes in all groups. FGF21 levels went in the opposite direction to glucose levels. In healthy people, FGF21 changes were inversely linked to insulin changes (P=0.012) and C-peptide changes (P=0.043); this link was not seen in prediabetes or type 2 diabetes. No relative or absolute effect sizes were reported.
What this means - more context
The study reports only P values and no effect sizes, so the size of the effect for a person cannot be calculated from the abstract. Absolute risk increases or absolute differences were not reported in this study.
To investigate acute changes in serum fibroblast growth factor 21 (FGF21) in response to a 75-g oral glucose challenge in humans.
In a 75-g oral glucose tolerance test among 20 healthy, 18 impaired glucose tolerance (IGT), and 21 type 2 diabetes mellitus (T2DM) subjects, fasting serum FGF21 rose progressively across groups (P<0.05 for global trend). After glucose intake, FGF21 showed a similar biphasic pattern in all groups: nadir at 60 min, peak at 180 min. FGF21 levels negatively correlated with glucose at multiple time points. In healthy subjects, fold changes in FGF21 were inversely associated with fold changes in insulin (P=0.012) and C-peptide (P=0.043), but not in IGT/T2DM. No relative or absolute effect sizes or absolute risks were reported.
Methods Used
A 75-g oral glucose tolerance test was performed in 20 healthy subjects, 18 with impaired glucose tolerance, and 21 with type 2 diabetes mellitus. Blood samples were collected for FGF21 and other biochemical parameters; associations of FGF21 with insulin and metabolic parameters were analyzed. Full methodology details not available in abstract.
Main Finding
Fasting serum FGF21 increased progressively from healthy to IGT to T2DM (P<0.05 for global trend). During OGTT, FGF21 fell to a nadir at 60 min and rose to a peak at 180 min in all groups. FGF21 levels negatively correlated with glucose levels. In healthy subjects, FGF21 fold change was inversely associated with insulin fold change (P=0.012) and C-peptide fold change (P=0.043), but not in IGT or T2DM. No relative or absolute effect sizes, confidence intervals, or absolute risk estimates were reported in the abstract.
Confidence Level
Limited - based on abstract only, full methodology not available; small sample, acute single-visit design, no effect sizes or CIs reported.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Small sample size (20 healthy, 18 IGT, 21 T2DM) and acute single-visit design
- •No effect sizes, confidence intervals, or absolute risk estimates reported in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
No practical action is supported by this abstract. It is an early mechanistic study; do not change diet, medication, or supplement use based on these findings.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 532 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study watched how a hormone called FGF21 changes after people drink a sugary drink. It found that the hormone and blood sugar/insulin levels move together, but it can't prove that the hormone causes those changes. We can only say they are linked, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Controlled oral glucose challenge with repeated measures
- Comparison across three glucose tolerance groups
- Measures of insulin and C-peptide alongside FGF21
Weaknesses
- Full methodology not available - based on abstract only
- Observational cross-sectional design
- No randomization
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study only included 59 people and we only read a short summary, not the full details. That means we don't know if there were problems with how the study was done, so we should be careful about trusting the results too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=59)+5.1/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 532 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. Observational cross-sectional design with no randomization or control group; cannot establish cause-effect relationships. Only associations can be inferred.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were declared in the provided study text.
The provided text does not include a conflict of interest, funding, or author affiliation section. This limits a full assessment, but no industry ties or conflicts are evident from the available information.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
8 researchersIf this is your work, this is how we attribute it on Fit Body Science. Zhuofeng Lin is listed as the lead author.